Article Text

Download PDFPDF
PAI-1/t-PA ratio in cord blood: a potential index of brain haemorrhage risk in extreme preterms
  1. Philippe Leroux1,
  2. Stéphane Marret1,2
  1. 1Laboratory of Microvascular Endothelium and Neonate Brain Lesions, Région Haute-Normandie-INSERM team ERI-28, Institute for Research and Innovation in Biomedicine, University of Rouen, Rouen, France
  2. 2Department of Neonatal Paediatrics and Intensive Care, Rouen University Hospital, Rouen, France
  1. Correspondence to Professor Stéphane Marret, Service de Pédiatrie Néonatale et de Réanimation, CHU Charles Nicolle, 1 rue de Germont, Rouen 76000, France; stéphane.marret@chu-rouen.fr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Although the incidence of subependymal haemorrhage/intraventricular haemorrhage (IVH)/intraparenchymal haemorrhage has decreased in recent years, it remains a good predictor of neurodevelopmental handicaps in very-preterm infants.1 Intraventricular blood leakage can result in hydrocephalus due to limited cerebrospinal fluid resorption, a consequence of fibrosis in the arachnoid granulation, subependymal basal lamina and perivascular spaces. The reference treatment approved for hydrocephalus is the ventriculoperitoneal shunt. A randomised trial of an alternative treatment procedure combining drainage and intraventricular fibrinolysis with recombinant tissue plasminogen activator (rt-PA) has been stopped because of haemorrhagic complications.

t-PA binds to low-density lipoprotein (LDL)-related receptor protein-1 (LRP1) promoting the induction of matrix metalloproteinase (MMP) 9. In addition, t-PA cleavage of plasminogen initiates proteolytic MMP cascade, resulting in degradation of …

View Full Text

Footnotes

  • Contributors PL and SM are responsible for reported research; PL and SM have participated in the concept and design, analysis and interpretation of data, drafting or revising of the manuscript, and have approved the manuscript as submitted.

  • Funding Rouen University Hospital Charles Nicolle, INSERM, Rouen University and FEDER.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Advice number CCPPRB: DGS 2006/0378 (7.08.2006).

  • Provenance and peer review Not commissioned; internally peer reviewed.